Education
About Us
Working with TipRanks
Follow Us
OptimizeRx Corporation (OPRX)
NASDAQ:OPRX
Total Valuation
OptimizeRx has a market cap or net worth of $154.02M. The enterprise value is $109.33M.
Market Cap$154.02M
Enterprise Value$109.33M
Share Statistics
OptimizeRx has 18.49M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18.49M
Owned by Insiders8.80%
Owned by Instutions27.43%
Financial Efficiency
OptimizeRx’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -9.19%.
Return on Equity (ROE)-17.19%
Return on Assets (ROA)-11.75%
Return on Invested Capital (ROIC)-9.19%
Return on Capital Employed (ROCE)-8.99%
Revenue Per Employee$719,750
Profits Per Employee-$157,101.563
Employee Count128
Asset Turnover0.54
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OptimizeRx is -4.42. OptimizeRx’s PEG ratio is -0.65.
PE Ratio-4.42
PS Ratio0.97
PB Ratio0.76
Price to Fair Value0.76
Price to FCF18.61
Price to Operating Cash Flow18.18
PEG Ratio-0.65
Income Statement
In the last 12 months, OptimizeRx had revenue of $92.13M and earned -$20.11M in profits. Earnings per share was -$1.10.
Revenue$92.13M
Gross Profit$58.31M
Operating Income-$13.71M
Pretax Income-$19.38M
Net Income-$20.11M
EBITDA-8.89M
Earnings Per Share (EPS)-1.10
Cash Flow
In the last 12 months, operating cash flow was $4.89M and capital expenditures -$450.00K, giving a free cash flow of $4.44M billion.
Operating Cash Flow$4.89M
Free Cash Flow$4.44M
Free Cash Flow per Share$0.24
Dividends & Yields
OptimizeRx pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield5.37%
Earnings Yield-22.62%
Stock Price Statistics
Beta1.97
52-Week Price Change-14.17%
50-Day Moving Average6.91
200-Day Moving Average6.95
Relative Strength Index (RSI)55.16
Average Volume (3m)935.86K
Important Dates
OptimizeRx upcoming earnings date is May 13, 2025, TBA.
Last Earnings DateMar 12, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
OptimizeRx as a current ratio of 2.89, with Debt / Equity ratio of 0.02
Current Ratio2.89
Quick Ratio2.89
Debt to Market Cap0.02
Net Debt to EBITDA1.24
Interest Coverage Ratio-2.23
Taxes
In the past 12 months, OptimizeRx has paid $725.00K in taxes.
Income Tax$725.00K
Effective Tax Rate-3.74%
Enterprise Valuation
OptimizeRx EV to EBITDA ratio is -8.76, with an EV/FCF ratio of 16.31.
EV to Sales0.85
EV to EBITDA-8.76
EV to Free Cash Flow16.31
EV to Operating Cash Flow15.93
Balance Sheet
OptimizeRx has $13.38M in cash and marketable securities with $2.38M in debt, giving a net cash position of -$11.00M billion.
Cash & Marketable Securities$13.38M
Total Debt$2.38M
Net Cash-$11.00M
Net Cash Per Share-$0.60
Tangible Book Value Per Share$2.52
Margins
Gross margin is 64.45%, with operating margin of -14.88%, and net profit margin of -21.83%.
Gross Margin64.45%
Operating Margin-14.88%
Pretax Margin-21.04%
Net Profit Margin-21.83%
EBITDA Margin-9.66%
EBIT Margin-14.36%
Analyst Forecast
The average price target for OptimizeRx is $11.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.67
Price Target Upside42.67%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast28.81%
EPS Growth Forecast-8.03%